Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 450008, Zhengzhou, China.
Cell Death Dis. 2021 Apr 14;12(4):401. doi: 10.1038/s41419-021-03690-z.
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors in the digestive system with a high incidence and poor prognosis. Long non-coding RNAs (LncRNA) have been reported to be closely associated with the occurrence and development of various human cancers. Data from GSE89102 shows an increase of THAP9-AS1 expression in ESCC. However, its functions and mechanisms underlying ESCC progression remain to be investigated. In this study, we found that THAP9-AS1 was overexpressed in ESCC tissues and cells. High THAP9-AS1 expression was positively correlated with tumor size, TNM stage, lymph node metastasis, and worse prognosis. Functionally, depletion of THAP9-AS1 suppressed cell proliferation, migration, and invasion, while enhanced apoptosis in vitro. Consistently, knockdown of THAP9-AS1 inhibited xenograft tumor growth in vivo. Mechanistically, THAP9-AS1 could serve as a competing endogenous RNA (ceRNA) for miR-133b, resulting in the upregulation of SOX4. Reciprocally, SOX4 bound to the promoter region of THAP9-AS1 to activate its transcription. Moreover, the anti-tumor property induced by THAP9-AS1 knockdown was significantly impaired due to miR-133b downregulation or SOX4 overexpression. Taken together, our study reveals a positive feedback loop of THAP9-AS1/miR-133b/SOX4 to facilitate ESCC progression, providing a potential molecular target to fight against ESCC.
食管鳞状细胞癌 (ESCC) 是消化系统中最常见的恶性肿瘤之一,发病率高,预后差。长链非编码 RNA (LncRNA) 已被报道与多种人类癌症的发生和发展密切相关。来自 GSE89102 的数据显示,THAP9-AS1 在 ESCC 中的表达增加。然而,其在 ESCC 进展中的功能和机制仍有待研究。在本研究中,我们发现 THAP9-AS1 在 ESCC 组织和细胞中表达上调。高 THAP9-AS1 表达与肿瘤大小、TNM 分期、淋巴结转移和预后不良呈正相关。功能上,THAP9-AS1 的耗竭抑制了细胞增殖、迁移和侵袭,同时增强了体外细胞凋亡。一致地,THAP9-AS1 的敲低抑制了体内异种移植肿瘤的生长。机制上,THAP9-AS1 可以作为 miR-133b 的竞争性内源 RNA (ceRNA),导致 SOX4 的上调。反过来,SOX4 结合到 THAP9-AS1 的启动子区域以激活其转录。此外,由于 miR-133b 的下调或 SOX4 的过表达,THAP9-AS1 敲低诱导的抗肿瘤特性明显受损。总之,我们的研究揭示了 THAP9-AS1/miR-133b/SOX4 的正反馈环促进 ESCC 进展,为对抗 ESCC 提供了一个潜在的分子靶点。